newsfilter
← Latest News
GlobeNewswire·

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S.